Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 3Classical hematology 2

Conditions

Anemia 2beta-Thalassemia 1Thrombocytosis 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × luspatercept × Clear all
NCT05005182 2024-09-19

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Mayo Clinic

Phase 2 Terminated
3 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Thrombocytosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

NCT02604433 2023-04-18

BELIEVE

Celgene

Phase 3 Completed
336 enrolled 38 charts 1 FDA

beta-Thalassemia

NCT02631070 2021-12-17

MEDALIST

Celgene

Phase 3 Completed
229 enrolled 36 charts 1 FDA
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡